Centers for Disease Control and Prevention. (2023). Testing for inhibitors and hemophilia.
Mahlangu, J. N., et al. (2017). Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors. Haemophilia.
MedlinePlus. (2022). Angioedema.
National Bleeding Disorders Foundation. (n.d.). Hemophilia A.
National Human Genome Research Institute. (2023). Genetic engineering.
National Human Genome Research Institute. (2023). Recombinant DNA technology.
National Organization for Rare Disorders. (2022). Acquired hemophilia.
National Organization for Rare Disorders. (2023). Hemophilia A.
Takeda Pharmaceuticals America, Inc. (2023). Obizur (antihemophilic factor- recombinant, porcine sequence kit) [package insert]. DailyMed.
